Evoleen

Evoleen operates as a venture builder, not a conventional fund. It co-creates healthtech ventures with pharma and medtech partners under a fee-for-service and shared-risk model. The firm takes equity stakes in the companies it builds and provides end-to-end services from strategy through clinical validation and market deployment.

CEO Chris Gugl drives the commercial and strategic direction, while CFO Andreas Csonka, who earlier worked in investment banking, oversees the firm's financial and investment structuring. The broader co-founder group — Christoph Schröter (COO) and Till Gerken (CTO) — controls regulatory and technical execution across portfolio ventures.

Evoleen's work spans more than 12 therapeutic areas including digital health, smart medical devices (Class I to III), neuroscience and behavioral health. The firm has confirmed ventures in diabetes integrated care, medication adherence, and remote monitoring via spinouts such as SIVA, Collabree, and Carity.

Yes. In addition to its Zurich headquarters, Evoleen maintains an office in Munich, Germany. The firm is active with partners across Europe, the United States, Asia and the Middle East, and in 2023 signed a collaboration agreement with the Saudi Arabia Ministry of Health's Model of Care.

Evoleen Access is a distinct unit within the Evoleen group, led by founder Michael Gschwandtner. It focuses solely on helping healthcare companies bring products through regulatory and quality-management hurdles — particularly ISO 13485 certification — without the full venture-building engagement.

Since 2018 more than 30 pharma and medtech companies have partnered with Evoleen. The firm publicizes relationships with former executives from Sanofi, Eli Lilly, and Sonova/Phonak among its advisors. It also collaborates with public institutions, hospitals, and NGOs on health-solution pilots and scaled roll-outs.

No. Evoleen is a privately held asset manager and venture builder founded by a group of operating executives, not a single- or multi-family office. The firm does not report managing a disclosed family fortune; its capital comes from corporate fees and equity interests in the ventures it creates.